Altss Research / Venture case 08
Olive AI
Olive announced a $4bn valuation when it closed a $400m round in July 2021. Waystar later reported buying certain Olive Clearinghouse and Patient Access assets on October 31, 2023, for $10m. That asset consideration cannot be treated as a valuation for the entire former company.
Altss Research · Evidence reviewed · Historical event record
Historical private valuation
$4bnIssuer-announced valuation accompanying closed $400m financing; pre/post-money not specified in issuer release.
Asset sale
$10mClearinghouse and Patient Access assets sold. Total consideration for certain Clearinghouse and Patient Access assets acquired by Waystar; not whole-company purchase price.
These figures have different valuation bases and dates. Their difference is not a measure of investor losses. Methodology ↗
The documented timeline
Private funding valuation disclosed
Issuer-announced valuation accompanying closed $400m financing; pre/post-money not specified in issuer release.
Clearinghouse and Patient Access assets sold
Total consideration for certain Clearinghouse and Patient Access assets acquired by Waystar; not whole-company purchase price.
Source documents
Publication and access dates identify the evidence used for this case.
Olive via PR Newswire · Primary source · Published Jul 1, 2021 · Accessed Oct 26, 2026
Waystar / SEC · Primary source · Published Feb 18, 2025 · Accessed Oct 26, 2026